Scientific Publications

Members of the Fisher Center have contributed to many diverse aspects of published literature addressing issues related to familial and hereditary cancers.  Representative citations are included below, divided by category.  PubMed identifiers (PMID) are also indicated.

Basic science, gene function, etc. 
  • Bae I, Rih JK, Kim HJ, Kang HJ, Haddad B, Kirilyuk A, Fan S, Avantaggiati ML, Rosen EM. BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle. 2005 Nov;4(11):1641-66. PMID: 16258266 
  • Ballal RD, Saha T, Fan S, Haddad BR, Rosen EM. BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage. J Biol Chem. 2009 Dec 25;284(52):36083-98. PMID: 19797051
  • Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat. 2010 May;121(1):227-31. PMID: 19697121
  • Cavalli LR, Man YG, Schwartz AM, Rone JD, Zhang Y, Urban CA, Lima RS, Haddad BR, Berg PE. Amplification of the BP1 homeobox gene in breast cancer. Cancer Genet Cytogenet. 2008 Nov;187(1):19-24. PMID: 18992636
  • Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet. 2004 Feb;149(1):38-43. PMID: 15104281 
  • Isaacs C, Cavalli LR, Cohen Y, Pennanen M, Shankar LK, Freedman M, Singh B, Liu M, Gallagher A, Rone JD, Dickson RB, Sidransky D, Haddad BR. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients. Breast Cancer Res Treat. 2004 Mar;84(2):99-105. PMID: 14999140 
  • Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM, Furth PA. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene. 2008 Jan 31;27(6):794-802. PMID: 17653086 
  • Katiyar P, Ma Y, Fan S, Pestell RG, Furth PA, Rosen EM. Regulation of progesterone receptor signaling by BRCA1 in mammary cancer. Nucl Recept Signal. 2006;4:e006. Epub 2006 Apr 28. PMID: 16741564 
  • Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol. 2007 Aug;21(8): 1905-23. PMID: 17505062 
  • Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol. 2006 Jan;20(1):14-34. PMID: 16109739 
  • Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer. 2005 Sep;12(3):533-48. Review. PMID: 16172191
  • Saha T, Smulson M, Rosen EM. BRCA1 regulation of base excision repair pathway. Cell Cycle. 2010 Jul 1;9(13):2471-2. PMID: 20581465
  • Saha T, Rih JK, Roy R, Ballal R, Rosen EM. Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem. 2010 Jun 18;285(25): 19092-105. PMID: 20185827
  • Saha T, Rih JK, Rosen EM. BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett. 2009 May 6;583(9):1535-43. PMID: 19364506
  • Silva Soares EW, de Lima Santos SC, Bueno AG, Cavalli IJ, Cavalli LR, Fouto Matias JE, de Souza Fonseca Ribeiro EM. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer. Cancer Genet Cytogenet. 2010 May;199(1):24-30. PMID: 20417865
  • Xiong J, Fan S, Meng Q, Schramm L, Wang C, Bouzahza B, Zhou J, Zafonte B, Goldberg ID, Haddad BR, Pestell RG, Rosen EM. BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol. 2003 Dec;23(23):8668-90.PMID: 14612409 
Clinical issues and non-genetic risk modifiers 
  • Dennis J, Ghadirian P, Little J, Lubinski J, Gronwald J, Kim-Sing C, Foulkes W, Moller P, Lynch HT, Neuhausen SL, Domchek S, Armel S, Isaacs C, Tung N, Sweet K, Ainsworth P, Sun P, Krewski D, Narod S; the Hereditary Breast Cancer Clinical Study Group. Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. Breast. 2010 Dec;19(6):479-84. PMID: 20541936
  • Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75. PMID: 20810374
  • Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, Olopade OI, Tomlinson G, Tung N, Blum JL, Couch F, Rebbeck TR. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Feb 24. [Epub ahead of print] PMID: 20180014
  • Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7. PMID: 18812548
  • Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, Zujewski JA, Prindiville S. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1696-701. PMID: 18583470 
  • Eng-Wong J, Zujewski JA. Raloxifene and its role in breast cancer prevention. Expert Rev Anticancer Ther. 2004 Aug;4(4):523-32. Review. PMID: 15270657
  • Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007 Dec;7(11):875-82. PMID: 18269778
  • Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Res Treat. 2009 Mar;114(1):127-35. PMID: 18483851 
  • Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10;26(8):1331-7. PMID: 18268356
  • Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control. 2008 Dec;19(10):1111-9. PMID: 18509731 
  • Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group, Garber J, Osborne M, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2007 Oct;105(2):221-8. PMID: 17245541
  • Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol. 2006 Jan;100(1):83-8. PMID: 16137751
  • Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005 Aug;16(6):667-74. PMID: 16049805 
  • Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7(5):R833-43. PMID: 16168130 
  • Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, Skates SJ, Gatsonis C. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007 Aug;244(2):381-8. PMID: 17641362
  • Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Mar 23. [Epub ahead of print] PMID: 20309627
  • Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P; Hereditary Breast Cancer Study Group, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22;99(2):371-4. PMID: 18577985 
  • Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P; Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol. 2006 May;7(5):402-6. PMID: 16648044
  • Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes W, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2006 Jan 1;118(1):103-7. PMID: 16032702
  • Nusbaum R, Vogel KJ, Ready K. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. Breast Dis. 2006-2007;27:21-50. Review. PMID: 17917139 
  • Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther. 2007;11(3):133-44. Review. PMID: 17570734 
  • Peshkin BN, Isaacs C. Evaluation and management of women with BRCA1/2 mutations. Oncology (Williston Park). 2005 Oct;19(11):1451-9; discussion 1459-68 1474. Review. PMID: 16370446
  • Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 1;24(16):2437-43. PMID: 16636335
  • Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 1;23(31):7804-10. PMID: 16219936
  • Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. PMID: 21893500
  • Spear SL, Willey SC, Feldman ED, Cocilovo C, Sidawy M, Al-Attar A, Hannan C, Seiboth L, Nahabedian MY. Nipple-sparing mastectomy for prophylactic and therapeutic indications. Plast Reconstr Surg. 2011 Jul 5. [Epub ahead of print] PubMed PMID: 21738086.
  • Smith KL, Isaacs C. Management of women at increased risk for hereditary breast cancer. Breast Dis. 2006-2007;27:51-67. Review. PMID: 17917140 
  • Spear SL, Schwarz KA, Venturi ML, Barbosa T, Al-Attar A. Prophylactic mastectomy and reconstruction: clinical outcomes and patient satisfaction. Plast Reconstr Surg. 2008 Jul;122(1):1-9. PMID: 18594352 
  • Spear SL, Carter ME, Schwarz K. Prophylactic mastectomy: indications, options, and reconstructive alternatives. Plast Reconstr Surg. 2005 Mar;115(3):891-909. Review. PMID: 15731693 
  • Spear SL, Pennanen M, Barter J, Burke JB. Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2-positive patient. Plast Reconstr Surg. 1999 Feb;103(2):548-53; discussion 554-5. PMID: 9950543
  • Vicus D, Rosen B, Lubinski J, Domchek S, Kauff ND, Lynch HT, Isaacs C, Tung N, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol. 2009 Oct;115(1):135-7. PMID: 19577280
  • Willey SC, Cocilovo C. Screening and follow-up of the patient at high risk for breast cancer. Obstet Gynecol. 2007 Dec;110(6):1404-16. Review. PMID: 18055740 
Ethics, health policy 
  • Fitzgerald KT. Ethics at the intersection of pharmacoethnicity. Clin Pharmacol Ther. 2008 Sep;84(3):424-6. PMID: 18596680 
  • Peshkin BN, Nusbaum RH, DeMarco TA.Genetic counseling about reproductive options for hereditary cancer: what is the standard of care? J Clin Oncol. 2007 Mar 1;25(7):911-2; author reply 913. PMID: 17327618 
  • Pollitz K, Peshkin BN, Bangit E, Lucia K. Genetic discrimination in health insurance: current legal protections and industry practices. Inquiry. 2007 Fall;44(3):350-68. PMID: 18038869 
Genetic counseling and testing, biobehavioral, quality of life 
  • DeMarco TA, Nusbaum RH, Peshkin BN, Patenaude AF, Schneider KA, Garber JE, Valdimarsdottir HB, Tercyak KP. Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together. Patient Educ Couns. 2010 Jan;78(1):29-33. PMID: 19545972
  • DeMarco TA, Peshkin BN, Valdimarsdottir HB, Patenaude AF, Schneider KA, Tercyak KP. Role of parenting relationship quality in communicating about maternal BRCA1/2 genetic test results with children. J Genet Couns. 2008 Jun;17(3):283-7. PMID: 18288593 
  • DeMarco TA, Smith KL, Nusbaum RH, Peshkin BN, Schwartz MD, Isaacs C. Practical aspects of delivering hereditary cancer risk counseling. Semin Oncol. 2007 Oct;34(5):369-78. Review. PMID: 17920890 
  • DeMarco TA, McKinnon WC. Life after BRCA1/2 testing: family communication and support issues. Breast Dis. 2006-2007;27:127-36. Review. PMID: 17917144 
  • DeMarco TA, Loffredo CA, Sampilo ML, Tercyak KP. On using a cancer center cancer registry to identify newly affected women eligible for hereditary breast cancer syndrome testing: practical considerations. J Genet Couns. 2006 Apr;15(2):129-36. PMID: 16761104
  • Graves KD, Christopher J, Harrison TM, Peshkin BN, Isaacs C, Sheppard VB. Providers' perceptions and practices regarding BRCA1/2 genetic counseling and testing in African American women. J Genet Couns. 2011 Aug 6. [Epub ahead of print] PMID: 21822773
  • Graves KD, Peshkin BN, Luta G, Tuong W, Schwartz MD. Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. Public Health Genomics. 2011;14(3):178-89. PMID: 21464556
  • Graves KD, Gatammah R, Peshkin BN, Krieger A, Gell C, Valdimarsdottir HB, Schwartz MD. BRCA1/2 genetic testing uptake and psychosocial outcomes in men. Fam Cancer. 2011 Jun;10(2):213-23. PMID: 21365268 
  • Graves KD, Wenzel L, Schwartz MD, Luta G, Wileyto P, Narod S, Peshkin BN, Marcus A, Cella D, Emsbo SP, Barnes D, Halbert CH. Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):648-54. PMID: 20200423
  • Graves KD, Moss LM, Jasper CL, DeMarco TA, Peshkin BN, Isaacs C, Schwartz MD. Predictors of enrollment into a familial cancer registry by individuals at high risk for BRCA1/2. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2763-7. PMID: 18086785 
  • Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat. 2007 Sep;104(3):321-9. PMID: 17066320
  • Lawrence WF, Peshkin BN, Liang W, Isaacs C, Lerman C, Mandelblatt JS. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):475-81. PMID: 11352857
  • Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008 Mar 1;26(7):1093-7. PMID: 18195327
  • O'Neill SC, Valdimarsdottir HB, Demarco TA, Peshkin BN, Graves KD, Brown K, Hurley KE, Isaacs C, Hecker S, Schwartz MD. BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat. 2010 Apr 10. [Epub ahead of print]. PMID: 20383578
  • O'Neill SC, Peshkin BN, Luta G, Abraham A, Walker LR, Tercyak KP. Primary care providers' willingness to recommend BRCA1/2 testing to adolescents. Fam Cancer. 2010 Mar;9(1):43-50. PMID: 19390990
  • O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology. 2009 Oct;18(10):1088-96. PMID: 19214961
  • O'Neill SC, DeMarco T, Peshkin BN, Rogers S, Rispoli J, Brown K, Valdimarsdottir H, Schwartz MD. Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. Am J Med Genet C Semin Med Genet. 2006 Nov 15;142C(4):251-9. PMID: 17024668 
  • Peshkin BN, Demarco TA, Tercyak KP. On the development of a decision support intervention for mothers undergoing BRCA1/2 cancer genetic testing regarding communicating test results to their children. Fam Cancer. 2010 Mar;9(1):89-97. PMID: 19609726
  • Peshkin BN, DeMarco TA, Garber JE, Valdimarsdottir HB, Patenaude AF, Schneider KA, Schwartz MD, Tercyak KP. Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). J Pediatr Psychol. 2009 Jul;34(6):627-38. PMID: 18385162
  • Peshkin BN, Demarco TA, Graves KD, Brown K, Nusbaum RH, Moglia D, Forman A, Valdimarsdottir H, Schwartz MD. Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test. 2008 Mar;12(1):37-52. PMID: 18373403
  • Rini C, O'Neill SC, Valdimarsdottir H, Goldsmith RE, Jandorf L, Brown K, DeMarco TA, Peshkin BN, Schwartz MD. Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results. Health Psychol. 2009 Sep;28(5):569-78. PMID: 19751083
  • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2011 Jun 29. doi: 10.1002/cncr.26294. [Epub ahead of print] PMID: 21717445.
  • Schwartz MD, Valdimarsdottir HB, DeMarco TA, Peshkin BN, Lawrence W, Rispoli J, Brown K, Isaacs C, O’Neill SO, Shelby R, Grumet SC, McGovern MM, Rogers S, Bremer H, Leaman S, O’Mara K, Komaridis K. Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol. 2009 Jan;28(1):11-9. PMID: 19210013
  • Schwartz MD, Peshkin BN, Tercyak KP, Taylor KL, Valdimarsdottir H. Decision making and decision support for hereditary breast-ovarian cancer susceptibility. Health Psychol. 2005 Jul;24(4 Suppl):S78-84. Review. PMID: 16045423 
  • Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, Halbert CH, Pennanen M, Finch C. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1003-7. PMID: 15824179 
  • Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004 May 15;22(10):1823-9. PMID: 15067026 
  • Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 2002 Jan 15;20(2):514-20. PMID: 11786581
  • Sussner KM, Edwards TA, Thompson HS, Jandorf L, Kwate NO, Forman A, Brown K, Kapil-Pair N, Bovbjerg DH, Schwartz MD, Valdimarsdottir HB. Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City. Public Health Genomics. 2011;14(6):356-70. PMID: 21540561.
  • Sussner KM, Thompson HS, Jandorf L, Edwards TA, Forman A, Brown K, Kapil-Pair N, Bovbjerg DH, Schwartz MD, Valdimarsdottir HB. The influence of acculturation and breast cancer-specific distress on perceived barriers to genetic testing for breast cancer among women of African descent. Psychooncology. 2009 Sep;18(9):945-55. PMID: 19090507
  • Tercyak KP, Hensley Alford S, Emmons KM, Lipkus IM, Wilfond BS, McBride CM. Parents' attitudes toward pediatric genetic testing for common disease risk. Pediatrics. 2011 May;127(5):e1288-95. PubMed PMID: 21502235;PubMed Central PMCID: PMC3081191.
  • Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007 Jan 20;25(3):285-91. PMID: 17159191 
  • Tercyak KP, Peshkin BN, Demarco TA, Patenaude AF, Schneider KA, Garber JE, Valdimarsdottir HB, Schwartz MD. Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. Genet Test. 2007 Fall;11(3):249-55. PMID: 17949286 
Genetic epidemiology including genetic risk modifiers
  • Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL,Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec1;70(23):9742-54. PMID: 21118973.
  • Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, Shields PG, Freudenheim JL. Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2010 Jul 30. [Epub ahead of print] PMID: 20676755.
  • Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M, Shields PG, Freudenheim JL. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control. 2010 Sep;21(9):1503-12.PMID: 20499154
  • Brewster AM, Jorgensen TJ, Ruczinski I, Huang HY, Hoffman S, Thuita L, Newschaffer C, Lunn RM, Bell D, Helzlsouer KJ. Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln andArg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat. 2006 Jan;95(1):73-80. PMID: 16319991
  • Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther. 2009 Apr;8(8):665-70. Review. PMID: 19287209.
  • Jorgensen TJ, Helzlsouer KJ, Clipp SC, Bolton JH, Crum RM, Visvanathan K. DNA repair gene variants associated with benign breast disease in high cancer risk women. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):346-50. PMID: 19124519.
  • Jorgensen TJ, Visvanathan K, Ruczinski I, Thuita L, Hoffman S, Helzlsouer KJ. Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland. Breast Cancer Res Treat. 2007 Jan;101(1):65-71. PMID: 16823510.
  • Kosti O, Byrne C, Meeker KL, Watkins KM, Loffredo CA, Shields PG, Schwartz MD, Willey SC, Cocilovo C, Zheng YL. Mutagen sensitivity, tobacco smoking and breast cancer risk: a case-control study. Carcinogenesis. 2010 Apr;31(4):654-9. PMID: 20110285
  • Marian C, Ochs-Balcom HM, Nie J, Kallakury BV, Ambrosone CB, Trevisan M, Edge S, Shields PG, Freudenheim JL. FGFR2 intronic SNPs and breast cancer risk; associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer. 2010 Sep 17. [Epub ahead of print] PMID: 20853316
  • Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011Aug;20(8):1690-702. PubMed PMID: 21708937.
  • Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G; kConFab, Singer CF, Pfeiler G, Neuhausen SL, Lynch HT, Garber JE, Weitzel JN, Isaacs C, Couch F, Narod SA, Rubinstein WS, Tomlinson GE, Ganz PA, Olopade OI, Tung N, Blum JL, Greenberg R, Nathanson KL, Daly MB. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15;69(14):5801-10. PMID: 19584272
  • Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, Hudis C, Offit K, Robson M. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res. 2007 Jul 15;13(14):4306-10. PMID: 17634561